MENU
+Compare
CYCC
Stock ticker: NASDAQ
AS OF
Apr 24, 04:59 PM (EDT)
Price
$0.23
Change
-$0.00 (-0.00%)
Capitalization
47.48M

CYCC Cyclacel Pharmaceuticals Forecast, Technical & Fundamental Analysis

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases... Show more

Industry: #Biotechnology
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CYCC with price predictions
Apr 23, 2025

Momentum Indicator for CYCC turns positive, indicating new upward trend

CYCC saw its Momentum Indicator move above the 0 level on April 22, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned positive. In of the 79 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CYCC's RSI Indicator exited the oversold zone, of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 70 cases where CYCC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CYCC just turned positive on April 17, 2025. Looking at past instances where CYCC's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CYCC advanced for three days, in of 237 cases, the price rose further within the following month. The odds of a continued upward trend are .

CYCC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYCC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CYCC entered a downward trend on April 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.805) is normal, around the industry mean (14.056). P/E Ratio (0.000) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (28.490) is also within normal values, averaging (252.992).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CYCC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CYCC is expected to report earnings to rise 25.24% to -41 cents per share on March 27

Cyclacel Pharmaceuticals CYCC Stock Earnings Reports
Q4'23
Est.
$-0.41
Q4'24
Beat
by $5.75
Q3'23
Missed
by $0.13
Q2'23
Beat
by $0.06
Q1'23
Beat
by $0.20
The last earnings report on April 02 showed earnings per share of -33 cents, beating the estimate of -607 cents. With 361.67K shares outstanding, the current market capitalization sits at 47.48M.
A.I. Advisor
published General Information

General Information

a developer of mechanism-targeted drugs to treat human cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
200 Connell Drive
Phone
+1 908 517-7330
Employees
12
Web
https://cyclacel.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARCT12.630.46
+3.78%
Arcturus Therapeutics Holdings
CVU3.380.06
+1.81%
CPI Aerostructures
VVV34.260.51
+1.51%
Valvoline
BBVA13.970.18
+1.31%
Banco Bilbao Vizcaya Argentaria SA
UNIT4.700.05
+1.08%
Uniti Group

CYCC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCC has been loosely correlated with CKPT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCC jumps, then CKPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCC
1D Price
Change %
CYCC100%
+0.93%
CKPT - CYCC
52%
Loosely correlated
N/A
MIRM - CYCC
36%
Loosely correlated
+0.42%
ORMP - CYCC
30%
Poorly correlated
+0.66%
IMMP - CYCC
27%
Poorly correlated
+5.88%
RNAC - CYCC
26%
Poorly correlated
+3.37%
More